Karyopharm Therapeutics (KPTI) Trading 8.3% Higher

Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares traded up 8.3% during trading on Tuesday . The stock traded as high as $4.47 and last traded at $4.46. 1,349,465 shares were traded during trading, a decline of 19% from the average session volume of 1,668,574 shares. The stock had previously closed at $4.12.

Several research analysts have commented on the stock. Wedbush lowered their price target on shares of Karyopharm Therapeutics from $19.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, February 25th. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Thursday, January 10th. HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Monday, December 3rd. BidaskClub cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. Finally, JPMorgan Chase & Co. cut shares of Karyopharm Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $21.00 to $7.00 in a report on Friday, March 1st. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $18.40.

The stock has a market capitalization of $256.19 million, a price-to-earnings ratio of -1.42 and a beta of 3.42.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, February 28th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.09). Karyopharm Therapeutics had a negative return on equity of 104.50% and a negative net margin of 502.90%. On average, sell-side analysts predict that Karyopharm Therapeutics Inc will post -3.56 earnings per share for the current year.

In other news, major shareholder Ltd Chione sold 800,000 shares of the business’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $4.99, for a total transaction of $3,992,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sharon Shacham sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $10.23, for a total transaction of $127,875.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,294,143 shares of company stock valued at $11,246,578 in the last 90 days. Insiders own 13.26% of the company’s stock.

Several large investors have recently modified their holdings of KPTI. Bank of America Corp DE lifted its position in shares of Karyopharm Therapeutics by 70.3% during the 2nd quarter. Bank of America Corp DE now owns 76,448 shares of the company’s stock worth $1,299,000 after buying an additional 31,556 shares during the last quarter. California Public Employees Retirement System purchased a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $339,000. Wells Fargo & Company MN lifted its position in shares of Karyopharm Therapeutics by 14.1% during the 3rd quarter. Wells Fargo & Company MN now owns 42,274 shares of the company’s stock worth $720,000 after buying an additional 5,239 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its position in Karyopharm Therapeutics by 20.9% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,090 shares of the company’s stock valued at $683,000 after purchasing an additional 6,920 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. raised its position in Karyopharm Therapeutics by 120.6% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 1,085,500 shares of the company’s stock valued at $18,486,000 after purchasing an additional 593,500 shares during the last quarter. Institutional investors and hedge funds own 75.79% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first reported by WKRB News and is the property of of WKRB News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.wkrb13.com/2019/03/13/karyopharm-therapeutics-kpti-trading-8-3-higher.html.

About Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

See Also: Debt-To-Equity Ratio

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.